December 2006
Worldwide Biotech;Dec2006, Vol. 18 Issue 12, p6
Trade Publication
The article reports on the failure of CellCept in treating myasthenia gravis to meet both primary and secondary endpoints in its phase III clinical trial according to Aspreva Pharmaceuticals Corp. The trial was designed to evaluate the efficacy and safety of mycophenolate mofetil in maintaining or improving symptom control with reduced doses of corticosteroids in patients with myasthenia gravis. CellCept is the leading immunosuppressant or anti-rejection drug of Roche used in combination with other immunosupressive drugs.


Related Articles

  • Immunosuirnressant drugs for mvasthenia aravis. Hart, I. K.; Sharshar, T.; Sathasivam, S. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2009, Vol. 80 Issue 1, p5 

    Along with corticosteroids, immunosuppressant drugs are mainstays of disease-modifying therapy for myasthenia gravis (MG). However, their efficacies and optimum use are unclear. We identified seven randomised controlled trials (ACT) of immunosuppressants in generalised MG that qualified for...

  • Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. Sorgun, Mine; Sener, Huseyin; Yucesan, Canan; Yucemen, Nezih // Neurological Sciences;Jun2014, Vol. 35 Issue 6, p891 

    Intravenous immunoglobulin (IVIg) treatment for acute exacerbations of Myasthenia Gravis (MG) was shown in several open-label studies. There are only two studies demonstrating the efficiency of regular intermittent IVIg therapy on MG patients who are not in their acute attack periods. Thirteen...

  • Outcomes of Preoperative and Postoperative Corticosteroid Therapies in Myasthenia Gravis. Jing, Yun; Liu, Xinxin; Yu, Lei; Li, Ran // European Neurology;Aug2017, Vol. 78 Issue 1/2, p86 

    Aims: To compare the long-term outcomes of non-thymomatous myasthenia gravis (MG) patients receiving pre-thymectomy (Pre-CS) or post-thymectomy corticosteroid (Post-CS) therapy. Methods: In a retrospective cohort study, 41 patients with MG were treated with Pre-CS therapy, and 110 were treated...

  • 2nd Phase III CellCept Failure Sends Aspreva Shares Down. Morrison, Trista // BioWorld Today;6/28/2007, Vol. 18 Issue 125, p1 

    The article reports on a decrease in the shares of Aspreva Pharmaceuticals Corp. after it revealed that the induction portion of a Phase III clinical trial of CellCept failed. It states that the trial has failed to establish the superiority of CellCept to intravenous cyclophosphamide (IVC), a...

  • The natural course of myasthenia gravis. Fonseca, V.; Havard, C.W.H. // BMJ: British Medical Journal (International Edition);6/2/90, Vol. 300 Issue 6737, p1409 

    Examines the use of thymectomy, corticosteroid and immunosuppressive agents in the treatment of myasthenia gravis in Great Britain. Reduction of morbidity; Requirement of long duration of treatment; Beneficial effects of the drugs.

  • Current and Future Standards in Treatment of Myasthenia Gravis Gold, Ralf; Schneider-Gold, Christiane // Neurotherapeutics;Oct2008, Vol. 5 Issue 4, p535 

    Summary: Myasthenia gravis (MG) is a prototypic antibody-mediated neurological autoimmune disorder. Herein we characterize modern treatment algorithms that are adapted to disease severity, and introduce the current principles of escalating strategies for MG treatment. In non-thymoma patients...

  • Early Aggressive Therapy for Myasthenia Gravis. Rubin, Michael // Neurology Alert;Mar2011, Vol. 29 Issue 7, p50 

    CAN EARLY AGGRESSIVE THERAPY (EAT) IMPROVE THE LONG-term outcome of newly diagnosed myasthenia gravis (MG)? EAT was defined as a single plasma exchange, followed by 1 g intravenous methylprednisolone, immediately, and on the two subsequent mornings, followed by low-dose oral corticosteroids to...

  • Early Aggressive Treatment Strategy against Myasthenia Gravis. Nagane, Yuriko; Suzuki, Shigeaki; Suzuki, Norihiro; Utsugisawa, Kimiaki // European Neurology;2011, Vol. 65 Issue 1, p16 

    Background/Aims: In treating myasthenia gravis (MG), our aims were to achieve early minimal manifestations (MM) by performing early aggressive therapy (EAT) using plasmapheresis and high-dose intravenous methylprednisolone, and then to maintain the status with low-dose oral corticosteroids (EAT...

  • Tratamiento de la glomeruloesclerosis focal y segmentaria idiopática: opciones en caso de resistencia a corticosteroides y anticalcineurínicos. Segarra-Medrano, Alfonso; Jatem-Escalante, Elias; Agraz-Pamplona, Irene; Carnicer-Cáceres, Clara; Ramos-Terrades, Natalia; Ostos-Roldán, Elena; Teresa Quiles-Pérez, M.; Antonia Arbós-Via, M. // Nefrologia;2013, Vol. 33 Issue 4, p448 

    Half of patients with nephrotic syndrome caused by primary focal segmental glomerulosclerosis (FSGS) have resistance to treatment with steroids. In the case of corticosteroid resistance, the best evidence-based option has classically been treatment with calcineurin inhibitors, although recent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics